Roxadustat y daprodustat para el manejo de la anemia en la enfermedad renal crónica

Abstract

Introduction: Hypoxia-inducible factor prolyl hydroxylase inhibitors are a new class of oral drugs used for the treatment of anemia in chronic kidney disease. They stimulate the production of endogenous erythropoietin, by stabilizing the hypoxia-inducible factor, a transcription factor responsible for the induction of genes that are necessary for cellular adaptation to hypoxia. Hypoxia-inducible factor also regulates the gene encoding divalent metal transporter 1 and duodenal cytochrome B, which regulates iron transport from the intestinal lumen to enterocytes. In addition, these drugs also have the ability to reduce hepcidin production and increase iron utilization, resulting in a decreased need for iron supplementation. Objective: to describe the advantages and disadvantages of roxadustat and daprodustat for the management of anemia in chronic kidney disease. Methodology: Descriptive bibliographic review. The information search was carried out in scientific databases such as PubMed, Epistemonikos, ScienceDirect, Web of Science, using inclusion and exclusion criteria, selecting articles from the last 5 years, in Spanish and English. Results: prolyl hydroxylase inhibitors such as roxadustat and daprodustat have been shown to be well tolerated in patients with chronic kidney disease dependent on dialysis and have an effect similar to that of erythropoiesis-stimulating agents in increasing hemoglobin levels